Complement therapeutics [electronic resource] / John D. Lambris, V. Michael Holers, Daniel Ricklin, editors.
This book highlights progress and trends in the rapidly evolving field of complement-related drug discovery and spotlights examples of clinical applications. As an integral part of innate immunity and critical mediator in homeostatic and inflammatory processes, the human complement system has been i...
Saved in:
| Online Access: |
Full Text (via Springer) |
|---|---|
| Other Authors: | , , |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
New York :
Springer,
©2013.
|
| Series: | Advances in experimental medicine and biology ;
735. |
| Subjects: |
MARC
| LEADER | 00000cam a2200000xa 4500 | ||
|---|---|---|---|
| 001 | b7198832 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 121002s2013 nyu ob 101 0 eng d | ||
| 005 | 20240418144332.0 | ||
| 019 | |a 788251399 |a 815276823 | ||
| 020 | |a 9781461441182 |q (electronic bk.) | ||
| 020 | |a 1461441188 |q (electronic bk.) | ||
| 020 | |a 146144117X | ||
| 020 | |a 9781461441175 | ||
| 020 | |z 9781461441175 | ||
| 035 | |a (OCoLC)spr811619688 | ||
| 035 | |a (OCoLC)811619688 |z (OCoLC)788251399 |z (OCoLC)815276823 | ||
| 037 | |a spr10.1007/978-1-4614-4118-2 | ||
| 040 | |a GW5XE |b eng |e pn |c GW5XE |d YDXCP |d COO |d E7B |d OCLCQ |d OHS |d UKMGB |d ZMC |d N$T |d VMC |d OCLCF |d NLGGC |d MKC |d DLC |d BTCTA |d OHX |d SIRPL |d HMS |d MMU |d VVL |d DEBSZ |d OCLCQ |d OCLCO |d OCL |d OCLCO |d OCLCA | ||
| 049 | |a GWRE | ||
| 050 | 4 | |a RM301.63 |b .C66 2013 | |
| 245 | 0 | 0 | |a Complement therapeutics |h [electronic resource] / |c John D. Lambris, V. Michael Holers, Daniel Ricklin, editors. |
| 260 | |a New York : |b Springer, |c ©2013. | ||
| 300 | |a 1 online resource. | ||
| 336 | |a text |b txt |2 rdacontent. | ||
| 337 | |a computer |b c |2 rdamedia. | ||
| 338 | |a online resource |b cr |2 rdacarrier. | ||
| 490 | 1 | |a Advances in experimental medicine and biology, |x 0065-2598 ; |v v. 735. | |
| 505 | 0 | 0 | |t Progress and Trends in Complement Therapeutics / |r Daniel Ricklin and John D. Lambris -- |t Inhibition of the Serine Proteases of the Complement System / |r Péter Gál, József Dobó, László Beinrohr, Gábor Pál and Péter Závodszky --The |t Role of MASP-1/3 in Complement Activation / |r Hideharu Sekine, Minoru Takahashi, Daisuke Iwaki and Teizo Fujita -- |t Membrane-Bound Complement Regulatory Proteins as Biomarkers and Potential Therapeutic Targets for SLE / |r Nibhriti Das, Bintili Biswas and Rohan Khera -- |t DAF as a Therapeutic Target for Steroid Hormones: Implications for Host-Pathogen Interactions / |r Bogdan Nowicki and Stella Nowicki -- |t Targeting gC1qR Domains for Therapy Against Infection and Inflammation / |r Berhane Ghebrehiwet, Jolyon Jesty, Rama Vinayagasundaram, Uma Vinayagasundaram and Yan Ji, et al. --The |t Alternative C5a Receptor Function / |r Hiroshi Nishiura --The |t Effects of Selective Complement and CD14 Inhibition on the E. coli-Induced Tissue Factor mRNA Upregulation, Monocyte Tissue Factor Expression, and Tissue Factor Functional Activity in Human Whole Blood / |r O.-L. Brekke, C. Waage, D. Christiansen, H. Fure and H. Qu, et al. |
| 505 | 8 | 0 | |t CR2-Mediated Targeting of Complement Inhibitors: Bench-to-Bedside Using a Novel Strategy for Site-Specific Complement Modulation / |r V. Michael Holers, Bärbel Rohrer and Stephen Tomlinson -- |t Paroxysmal Nocturnal Hemoglobinuria and the Complement System: Recent Insights and Novel Anticomplement Strategies / |r Antonio M. Risitano -- |t Defective Complement Action and Control Defines Disease Pathology for Retinal and Renal Disorders and Provides a Basis for New Therapeutic Approaches / |r Peter F. Zipfel and Nadine Lauer -- |t C3 Glomerulonephritis/CFHR5 Nephropathy Is an Endemic Disease in Cyprus: Clinical and Molecular Findings in 21 Families / |r Constantinos Deltas, Daniel Gale, Terence Cook, Konstantinos Voskarides and Yiannis Athanasiou, et al. -- |t Complement-Targeted Therapeutics in Periodontitis / |r George Hajishengallis and John D. Lambris -- |t Complement System Activation in Cardiac and Skeletal Muscle Pathology: Friend or Foe? / |r Maro Syriga and Manolis Mavroidis. |
| 505 | 8 | 0 | |t Innate Immunity as Orchestrator of Bone Marrow Homing for Hematopoietic Stem/Progenitor Cells / |r Mariusz Z. Ratajczak, ChiHwa Kim, Janina Ratajczak and Anna Janowska-Wieczorek -- |t Complement-Mediated Microvascular Injury Leads to Chronic Rejection / |r Mohammad A. Khan and Mark R. Nicolls -- |t Targeting Complement at the Time of Transplantation / |r Steven Sacks, Julia Karegli, Conrad A. Farrar, Elham Asgari and Wilhelm Schwaeble, et al. -- |t Evaluation of the Blood Compatibility of Materials, Cells, and Tissues: Basic Concepts, Test Models, and Practical Guidelines / |r Kristina N. Ekdahl, Jaan Hong, Osama A. Hamad, Rolf Larsson and Bo Nilsson -- |t Noninvasive Detection of Complement Activation Through Radiologic Imaging / |r Joshua M. Thurman and Bärbel Rohrer -- |t Highly Multiplexed Proteomic Platform for Biomarker Discovery, Diagnostics, and Therapeutics / |r Michael R. Mehan, Rachel Ostroff, Sheri K. Wilcox, Fintan Steele and Daniel Schneider, et al. -- |t Complement in Action: An Analysis of Patent Trends from 1976 Through 2011 / |r Kun Yang, Robert A. DeAngelis, Janet E. Reed, Daniel Ricklin and John D. Lambris. |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | 0 | |g Part 1. Introduction -- |t Simplistic theory of the functions of the ensemble of the electrons, atoms, molecules, nuclei, in the brain -- |t Practical illustrations -- |t Quantum spin dynamics and the MRI --The |t density matrix concept --The |t imaging -- |t Future horizons of the brain science --Summary and conclusion -- |g Part 2. Introduction -- |t Biomedical diamagnetic spin and electric-qudrupole interaction systems -- |t Practical illustrations sodium spectroscopy and imaging: clinical applications -- |t Summary and discussion -- Conclusion and future horizons. |
| 520 | |a This book highlights progress and trends in the rapidly evolving field of complement-related drug discovery and spotlights examples of clinical applications. As an integral part of innate immunity and critical mediator in homeostatic and inflammatory processes, the human complement system has been identified as contributor to a large number of disorders including ocular, cardiovascular, metabolic, autoimmune, and inflammatory diseases as well as in ischemia/reperfusion injury, cancer and sepsis. In addition, complement is often involved in adverse immune reactions to biomaterials, cell and organ transplants or drug delivery systems. Although the complement cascade with its close to 50 extracellular protein targets has long been recognized as an attractive system for therapeutic modulation, the past few years have seen a particularly strong boost in interest. Fueled by novel research insight and the marketing of the first complement-targeted drugs, a plethora of highly creative treatment approaches and potent drug candidates have recently emerged and are currently evaluated in disease models and clinical trials. The chapters in this book cover a wide range of topics related to the development of complement therapeutics, ranging from the molecular and functional description of complement targets to the presentation of novel inhibitors, improved treatment strategies as well as examples of disease models and clinical applications. The broad and up-to-date overview on a highly versatile and dynamic field renders this book an indispensable source of information for researchers and clinicians dealing with therapeutic and disease-related aspects of the human complement system. | ||
| 650 | 0 | |a Drug targeting. |0 http://id.loc.gov/authorities/subjects/sh88005350. | |
| 650 | 0 | |a Drug development. |0 http://id.loc.gov/authorities/subjects/sh97007921. | |
| 650 | 7 | |a Drug development. |2 fast |0 (OCoLC)fst00898670. | |
| 650 | 7 | |a Drug targeting. |2 fast |0 (OCoLC)fst00898709. | |
| 700 | 1 | |a Lambris, J. D. |q (John D.) |0 http://id.loc.gov/authorities/names/n89124132 |1 http://isni.org/isni/0000000066459763. | |
| 700 | 1 | |a Holers, V. Michael, |d 1952- |0 http://id.loc.gov/authorities/names/n98802566 |1 http://isni.org/isni/0000000114601905. | |
| 700 | 1 | |a Ricklin, Daniel. |0 http://id.loc.gov/authorities/names/no2013012394 |1 http://isni.org/isni/0000000401559965. | |
| 776 | 0 | 8 | |i Print version: |t Complement therapeutics. |d New York : Springer, ©2013 |w (DLC) 2012945942. |
| 830 | 0 | |a Advances in experimental medicine and biology ; |v 735. |0 http://id.loc.gov/authorities/names/n42001229. | |
| 856 | 4 | 0 | |u https://colorado.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-1-4614-4118-2 |z Full Text (via Springer) |
| 907 | |a .b71988324 |b 01-16-21 |c 10-15-12 | ||
| 998 | |a web |b 05-01-17 |c g |d b |e - |f eng |g nyu |h 0 |i 1 | ||
| 907 | |a .b71988324 |b 07-02-19 |c 10-15-12 | ||
| 944 | |a MARS - RDA ENRICHED | ||
| 907 | |a .b71988324 |b 07-06-17 |c 10-15-12 | ||
| 907 | |a .b71988324 |b 05-23-17 |c 10-15-12 | ||
| 915 | |a I | ||
| 956 | |a Springer e-books | ||
| 956 | |b Springer Nature - Springer Biomedical and Life Sciences eBooks 2013 English International | ||
| 956 | |b Springer Nature - Springer Biomedical and Life Sciences eBooks 2013 English International | ||
| 999 | f | f | |i 478b6d55-e0c3-56dd-863e-1e11949aba92 |s fb1265d4-9068-52cd-a498-10e37028a2ca |
| 952 | f | f | |p Can circulate |a University of Colorado Boulder |b Online |c Online |d Online |e RM301.63 .C66 2013 |h Library of Congress classification |i Ebooks, Prospector |n 1 |